4583
Chiome Bioscience Inc.
カイオム・バイオサイエンス
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Dec 2021
712,932
Dec 2022
630,815
Dec 2023
682,464
Dec 2024
780,809
Dec 2025
593,290
Operating profit(thousand JPY)
Dec 2021
-1,334,319
Dec 2022
-1,258,655
Dec 2023
-1,205,168
Dec 2024
-1,030,869
Dec 2025
-979,774
Operating profit margin(%)
Dec 2021
-187.16
Dec 2022
-199.53
Dec 2023
-176.59
Dec 2024
-132.03
Dec 2025
-165.14
Profit before tax(thousand JPY)
Dec 2021
-1,466,400
Dec 2022
-1,237,861
Dec 2023
-1,215,008
Dec 2024
-1,017,536
Dec 2025
-979,539
Profit(thousand JPY)
Dec 2021
-1,479,895
Dec 2022
-1,242,871
Dec 2023
-1,220,018
Dec 2024
-1,020,776
Dec 2025
-982,779
Total assets(thousand JPY)
Dec 2021
2,339,439
Dec 2022
2,215,470
Dec 2023
1,751,454
Dec 2024
2,468,857
Dec 2025
1,727,504
Cash and cash equivalents(thousand JPY)
Dec 2021
1,790,988
Dec 2022
1,727,270
Dec 2023
1,325,554
Dec 2024
2,063,280
Dec 2025
1,205,026
Cash flows from operating activities(thousand JPY)
Dec 2021
-1,131,291
Dec 2022
-1,191,009
Dec 2023
-1,069,192
Dec 2024
-1,000,695
Dec 2025
-935,988
Cash flows from investing activities(thousand JPY)
Dec 2021
-35,384
Dec 2022
-
Dec 2023
173
Dec 2024
-
Dec 2025
-55,463
Cash flows from financing activities(thousand JPY)
Dec 2021
271,345
Dec 2022
1,127,291
Dec 2023
667,303
Dec 2024
1,738,421
Dec 2025
133,198
Return on equity(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Equity ratio(%)
Dec 2021
79.4
Dec 2022
80.2
Dec 2023
65.1
Dec 2024
77.4
Dec 2025
64.1
Earnings per share(JPY per share)
Dec 2021
-36.74
Dec 2022
-28.26
Dec 2023
-24.62
Dec 2024
-17.54
Dec 2025
-14.47
Net assets per share(JPY per share)
Dec 2021
45.55
Dec 2022
36.7
Dec 2023
21.66
Dec 2024
28.53
Dec 2025
16.18
Dividend per share(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.